A study published in the Journal of the American Medical Association states that before an individual is vaccinated with mRNA covid-19 vaccines, severe respiratory syndrome of coronavirus 2[SARS-CoV-2] was shown with a lower risk for breakthrough infection.
From collected data shows that almost 1,531,736 individuals were vaccinated with the BNT162b2 or mRNA-1273 vaccine from date Dec. 21, 2020, to Sep. 19, 2021, almost after 14 days of receipt of the second dose.
SARS-CoV-2 Infection Associated With Lower Risk
The BNT162b2 vaccine was received by 99,226 individuals but 290,432 among them matched without polymerase chain reaction infection. While the mRNA-1273 vaccinated by 58,096 individuals and 169,514 matched without prior PCR infection.
Individuals vaccinated before dose 1 with a prior infection of six months has a lower risk of Covid syndrome SARS-CoV-2 Infection. Comparatively, individuals infected less than 6 months before dose 1 have a higher risk for breakthrough infection. The estimated hazard ratio for BNT162b2 and mRNA-1273 is 0.62 and 0.40 respectively.
One author states that vaccinated individual with prior infection is a hybrid mixture of natural and vaccine immunity and associated with a reduction in breakthrough infection.
The results are not surprising as the effectiveness of vaccines was already proved in various other tests. However, the sustained results indicate that getting vaccines at the right time can not only prevent Covid infection but also other respiratory illnesses in the near future. The researchers have not worked on the booster dose and new developments may lead to advanced therapies in the future.
Research carried out found are persons vaccinated after SARS-CoV-2 infection better protect against breakthrough infection than that individuals vaccinated without prior infection. After a continuous study on this finding shows that prior SARS-CoV-2 infection was associated with a significantly reduced risk of breakthrough infection among vaccinated with both the BNT162b2 and mRNA-1273.
The effect of prior SARS-CoV-2 infection on vaccine protection is continuing in research to understand in a better way. The study compares infection risk between 2 vaccines one with short-term prior infection and the other with long-term prior infection. The comparison will provide better insights into the nature of infection in the long run.
Vaccine breakthrough before SARS-CoV-2 infection has been monitored in the number of healthcare vaccinated with 2 doses of BNT162b2 and mRNA-1273. Vaccine protection against prior SARS-CoV-2 infection is 83 percent in the overall population. A single dose of the vaccine is only able to boost protection against SARS-CoV-2 infection but one condition is applied. The individual must have previously been infected with the disease.
The finding published in the journal Science reveals that for those who have not previously been infected and till now not received a single dose of vaccine the immune response to infectious covid 19 strain will be ineffective.
The evidence resulted in that individual after receiving a single dose of vaccine, prior infection associated with neutralizing antibodies in response of vaccine protection which could provide prevention of SARS-CoV-2 infection. While people without previous SARS-CoV-2 infection a single dose of vaccine may not provide such power to neutralize antibodies compared to the previous infection.
These findings concluded vaccines are still able to defend against severe infection syndrome but in this case, the SARS-CoV-2 infection vaccine is more likely to boost protection with a prior form of infection. This will provide the immune system with much time to defend against infection.
According to WHO current vaccines can prevent severe disease but they do not block the infection at that point that’s why the virus is still capable of replicating its copies to a huge number. To defeat this advanced virus new generation of vaccines are required to block the transmission.
